Founded in 1949, Medtronic has grown to become the world's largest independent medical technology company. At the core of all we do is our Mission: to alleviate pain, restore health and extend life. It provides a clear path for all employees as we work together to take Medtronic to the next level.
Medtronic was first incorporated April 23, 1957 and became a public company as the result of a convertible debenture offering. The first shares were issued under these debentures on December 17, 1959 to our company founders, Earl Bakken and Palmer Hermundslie. Medtronic shares were traded Over-the-Counter (OTC) until we were listed on the NASDAQ in 1964. Medtronic began trading on the New York Stock Exchange on November 21, 1977 and continues to be traded on the NYSE today under the ticker symbol MDT.
Independent Analysis of Large and Comprehensive ENDEAVOR Program Shows Remarkably Durable Safety and Efficacy at Five Years of Follow Up in Coronary Artery Disease PatientsMINNEAPOLIS & ALTANTA, Mar 14, 2010 (BUSINESS WIRE) -- The consistency and quality of the long-term clinical results for the
Endeavor(R) drug-eluting stent (DES) from Medtronic, Inc.
(NYSE: MDT), continue to distinguish it as a treatment for coronary
artery disease, according to newly released data....
MINNEAPOLIS, Mar 12, 2010 (BUSINESS WIRE) -- The U.S. Food and Drug Administration (FDA) Neurological Devices Panel
today voted seven to five to recommend approval with conditions of Deep
Brain Stimulation (DBS) Therapy for Epilepsy from Medtronic, Inc. (NYSE:
MDT) as adjunctive treatment for partial-onset seizures in adults with
medically refractory epilepsy. If the FDA follows the recommendation of
the panel, the therapy will be approved for the treatmen...
Post-Market Evaluation of Breakthrough Medical Device Begins Enrolling Patients; First Implants Occur in GermanyMINNEAPOLIS, Mar 12, 2010 (BUSINESS WIRE) -- Moving to expand the evidence base for the future of structural heart disease therapy,Medtronic, Inc. (NYSE: MDT), today announced the start of the first of several new initiatives in a robust international clinical program for its CoreValve transcatheter aortic valve system, a minimally-invasive alternative to open-heart surgery for aortic ...
